ProMIS Neurosciences

ProMIS Neurosciences Assets per Share

The Total Assets per Share of ProMIS Neurosciences (PMN) as of Oct 27, 2026 is 6.33 USD. In the previous year, Total Assets per Share was 3.22 USD — a change of 96.81% (higher).

Assets per Share

6.33USD

YoY

96.81%

Last updated:

Total Assets per Share of ProMIS Neurosciences is 2023 6.33 USD. Total Assets per Share of ProMIS Neurosciences was 2022 3.22 USD. It decreases by 96.81% higher compared to the previous year.

The ProMIS Neurosciences Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2016
0.33 USD
Jan 1, 2017
0.80 USD
Jan 1, 2018
1.01 USD
Jan 1, 2019
0.74 USD
Jan 1, 2020
0.51 USD
Jan 1, 2021
8.26 USD
Jan 1, 2022
3.22 USD
Jan 1, 2023
6.33 USD
The ProMIS Neurosciences Assets per Share history
YEARAssets per ShareYoY
6.33USD+96.81%
3.22USD-61.01%
8.26USD+1,528.44%
0.51USD-31.88%
0.74USD-26.27%
1.01USD+25.43%
0.80USD+140.28%
0.33USD-13.25%
0.39USD+232.00%
0.12USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

Total Assets per Share of ProMIS Neurosciences is 6.33 USD in 2023.

Total Assets per Share of ProMIS Neurosciences changed from 3.22 USD to 6.33 USD, representing a 96.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences